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Abstract
Anti-angiogenic therapy, which suppresses tumor growth by disrupting oxygen and nutrient 
supply from blood to the tumor, is now widely accepted as a treatment for cancer. To investigate 
the mechanisms of action of these anti-angiogenesis drugs, new three dimensional (3D) cell 
culture-based drug screening models are increasingly employed. However, there is no in vitro 
high-throughput screening (HTS) angiogenesis assay that can provide uniform culture conditions 
for quantitative assessment of physiological responses to chemoattractant reagents under various 
concentrations of anti-angiogenesis drugs. Here we describe a method for screening and 
quantifying the vascular endothelial growth factor (VEGF)-induced chemotactic response on 
human umbilical vein endothelial cells (HUVECs) cultured under different concentrations of 
bortezomib, a selective 26S proteasome inhibitor. With this quantitative microfluidic angiogenesis 
screen (QMAS), we demonstrate that bortezomib-induced endothelial cell death was preceded by 
a series of morphological changes that develop over several days. We also explore the 
mechanisms by which bortezomib can inhibit angiogenesis.
Introduction
Drug screening technologies in two dimensions (2D) (i.e. as a flat layer of cells) have been 
widely adopted in the pharmaceutical industry for drug discovery. These approaches are still 
in use; however considerable challenges remain in identifying new drugs for cancer 
treatment in particular due to the critical role of multiple cell types in disease progression 
and the inability to accurately mimic the cellular environment in vivo [1–5]. 
Consequentially, a wide gap exists between 2D cell culture assays and animal testing [6]. 
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Moreover, pressures are mounting to reduce animal testing due to its expense, the long times 
required to obtain results, ethical considerations, and the limitations of an animal model for 
predicting human responses [7, 8]. In order to overcome the drawbacks of 2D cell culture 
assays and potentially reduce the need for animal testing, new analytical screening assays in 
three dimensions (3D) and employing human cells are needed. Cells in vivo are subject to 
multiple cues that vary in time and space, including gradients of cytokines and secreted 
proteins from neighboring cells of similar or different type, and their behavior is strongly 
influenced by mechanical and biochemical interactions with the extracellular matrix (ECM). 
To meet these challenges, microfluidic Lab-on-a-Chip (LOC) technologies offer promising 
strategies for addressing the inherent complexity of cellular systems with spatio-temporal 
multiple cues [9, 10]. In addition, microfluidic approaches have been adopted to create 3D 
tissue scaffolds with realistic physical, mechanical, and biological properties.
3D cell culture-based microfluidic devices have been previously reported, which enable the 
formation of cell spheroids in 3D for mimicking the complexity of heterogeneous tumor 
tissue, for cytotoxicity tests of anticancer drugs in the devices [11–15]. These systems could 
be used as a assay for screening anticancer drugs in cancer treatment, but, currently, anti-
angiogenic therapies (vascular-targeted therapies), which suppress tumor growth by cutting 
off supply of nutrients and oxygen in the blood to tumor cells, has emerged as an important 
advance in cancer treatment with a significant reduction in the adverse effects caused by 
other anti-cancer drugs [16–19]. The potential now exists to develop new approaches to anti-
angiogenesis drug screening, which enable monitoring and quantification of cell responses 
to the anti-angiogenesis drug in addition to screening for cell viability. Recent efforts have 
produced in vitro microfluidic cell culture models that apply physical and biochemical 
stimuli within a 3D hydrogel scaffold integrated in the channels and offer a viable solution 
for monitoring cellular behaviors in response to drug [17–31]. For example, these models 
have been employed to investigate heterotypic cell–cell interactions in 3D [22], to study 
neurite responses to growth factor gradients [23], to evaluate and quantify capillary 
sprouting and angiogenesis from an intact cell monolayer [24, 26], and to examine the 
effects of interstitial flow on cancer cell morphology and migration [26].
However, the previously developed microfluidic based-platforms are ill-suited to the 
purpose of screening the effects of various anti-angiogenesis drugs over a range of 
concentrations. For example, preparing and handling many previously developed 
microfluidic based-platforms can be time-consuming and tedious. Moreover, larger 
variability may occur between different chips due to slight variations in protocol caused by 
testing a large number of chips manually.
Here, we propose a new microfluidic platform (termed the quantitative microfluidic 
angiogenesis screen (QMAS)), that can monitor and quantify cellular behaviors, such as 
morphological changes, endothelial cell viability, and formation of angiogenic sprouts, 
depending on the various concentrations of drug applied (i.e., bortezomib, a selective 26S 
proteasome inhibitor). This model incorporates a perfusion culture-based system for 
generating stable concentration gradients in multiple 3D collagen matrices by generating a 
pressure-driven uniform flow rate through each of the microfluidic channels. We 
demonstrate these capabilities through a study of a drug, bortezomib, which is known to 
Kim et al. Page 2









inhibit angiogenesis in vivo. To gain insight into the anti-angiogenic effects of bortezomib 
on human umbilical vein endothelial cells (HUVECs), we monitored cell behaviors daily, 
and investigated the changes of morphological shape and viability of bortezomib-treated 
HUVEC under various concentrations of bortezomib. Capillary growth and the formation of 
circular lumen-like structures from an intact endothelial cell monolayer in response to 
vascular endothelial growth factor (VEGF) are quantified showing that the size and number 
of lumen-like structures are directly affected by the concentrations of bortezomib. We 
demonstrate that bortezomib inhibits angiogenesis in a dose-dependent manner and also that 
it causes cell death of HUVECs at sufficiently high concentrations.
Results and Discussion
Characterization of the QMAS for screening anti-angiogenic therapeutic drugs
Vascular sprouts grow from existing blood vessels into the interstitial matrix guided by a 
concentration gradient of factors (e.g., vascular endothelial growth factor (VEGF)) secreted 
from the tumor during tumor angiogenesis. When an anti-angiogenesis drug is employed in 
vivo for the treatment of cancer, it inhibits the formation of tumor-associated blood vessels; 
thereby disrupting the supporting perivascular niche for cancer stem cells [16–18] (Fig. 1A). 
This in vivo anti-angiogenic therapeutic process was modeled in the QMAS (Fig.1B & C) 
incorporating the following significant features: (1) 3D hydrogel scaffolds in gel cages 
(fourteen) mimic the extracellular matrix (ECM) in vivo, (2) confluent endothelial cell (ECs) 
monolayers in the cell culture channels (eight) mimic pre-existing blood vessels in vivo, (3) 
VEGF-supplemented media in conditioned media channels (seven) mimic the presence of 
growth factors (VEGF) secreted by tumor in vivo, and (4) bortezomib-supplemented media 
with various concentrations in the cell culture channels (eight) mimic the introduction of 
anti-angiogenesis drugs (i.e. bortezomib, a selective 26S proteasome inhibitor, marketed by 
Millennium Phamaceuticals as Velcade) in vivo via the circulation (Fig. 1B & Fig. 1C). The 
QMAS makes it possible for us to monitor, screen, and quantify the angiogenic responses in 
the 3D hydrogel scaffolds due to various concentrations of bortezomib.
The QMAS was fabricated using soft lithography and PDMS replica molding (Fig. S1, see 
Materials and Methods), and consists of: (1) reservoirs used for providing fresh conditioned 
media (VEGF-supplemented or Bortezomib-supplemented medias) into all the channels, 
made by cutting the end of commercial pipette tips (i.e. MBP (Molecular BioProducts)), and 
media in the reservoirs were replaced daily during cell culture using a multi-tip pipette, (2) a 
1st PDMS layer including microchannels for the bortezomib-supplemented media with 
various concentrations, endothelial cell monolayers and collagen gel-cages, (3) 2nd PDMS 
layer used only during filling as a manifold layer for filling collagen gel, and (4) a large 
cover slip at the bottom (TED PELLA, INC. 3 × 3 1/4″, Thick: 0.19 ~0.25mm) (Fig. S1A & 
S1B).
To mimic the presence of pro-angiogenic factors secreted from the tumor, VEGF (40ng/ml) 
was introduced into the QMAS, which then diffused into the 3D hydrogel scaffold regions 
(fourteen) simultaneously. However, establishing stable concentration profiles within the 
QMAS with integrated porous matrices required that we eliminate any interstitial flow 
across the matrix resulting from pressure imbalances and this proved challenging. To 
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achieve stability of concentration profiles, the QMAS was designed as a perfusion-based 
system. The stable concentration profiles could be created in the fourteen-3D hydrogel 
scaffold matrices by minimizing interstitial flow across them; this was accomplished by a 
combination of introducing identical volumetric flow rates into the fifteen-independent flow 
channels and connecting the ends of all flow channels to a single syringe pump at the 
common outlet-junction (Fig. S2A). The distribution of volumetric flow rates was controlled 
via design of the hydrodynamic resistance of the microchannels (Fig. S2B). Hydrodynamic 
simulation using a commercial finite element solver (COMSOL, Burlington, MA) was 
performed to confirm equal flows in each of the fifteen microchannels, and we confirmed 
that uniform flow rates were generated during perfusion (Fig. S2C).
Numerical simulations based on a transient solution of the Brinkman equation for porous 
medium flow and the convection-diffusion equation for a growth factor having the 
diffusivity of VEGF (D=5 ×10−11 m2/s) demonstrated the generation of a nearly linear 
concentration gradient of growth factor; details of numerical simulations are provided in SI 
Materials and Methods (Fig. S3). In order to maintain this gradient over the entire length of 
the gel regions, the media should be introduced at a flow rate corresponding to a Peclet 
number (Pe) > 50. To satisfy this condition, the withdrawal flow rate in the syringe pump 
(Infuse/Withdraw syringe pump, HARVARD) was set to 1.33 μl/min; we used this flow rate 
for all experiments.
In the previously developed systems as well as the QMAS, the collagen hydrogel was 
confined to the gel regions by a series of equally spaced posts (110 μm, Fig. 1C) that prevent 
liquid from leaking into adjacent channels. Generally, collagen gel filling by a pipette has 
been done manually; this is a simple method, but leakage between adjacent channels was 
sometimes difficult to avoid. In order to improve the consistency of filling, we modified the 
collagen gel filling method using the manifold layer that can insert the gel to the fourteen-
gel regions simultaneously (Fig. S4). When a collagen solution is injected into an inlet of the 
manifold layer by the syringe pump, the injected solution is distributed among the fourteen 
microchannels in the manifold layer (2nd PDMS layer), and then simultaneously enters into 
the fourteen collagen gel regions (1st PDMS layer) (Fig. S4A). Volumetric flow rates in the 
microchannel network of the manifold layer were controlled by specifying the dimensions, 
and thereby the hydrodynamic resistance, of the microchannels (Fig. S4B). We again 
demonstrated that the same volumetric flow rates were generated in the 14 collagen gel 
regions using hydrodynamic simulation (COMSOL Inc., MA, USA) (Fig. S4C). 
Experimentally, we observed that the consistency of collagen gel filling into the gel cages 
was influenced by the surface properties of the bottom layer; for example, a glass surface 
and PDMS surface behaved differently. When a PDMS surface was used as the bottom 
layer, collagen filling was more uniform than when glass was used due to its low wettability 
(data not shown). All reported experiments, however, were conducted with glass as the 
bottom layer to provide optimal imaging quality. Chip preparation details are provided in 
Materials & Methods and SI Movie 1.
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High throughput angiogenesis assay
To demonstrate the capabilities of the QMAS as an angiogenesis assay in response to 
chemoattractant gradients, VEGF-supplemented media (40 ng/ml) were introduced into the 
VEGF injection channels (#1, #3, #5, & #7) (Fig. S5 & Fig. 2A) and the control mediums 
without VEGF were injected into the VEGF injection channels (#2, #4, #6, & #7) as 
reference conditions (Fig. S5 & Fig. 2A). Response of HUVECs was monitored daily for 5 
days by phase-contrast microscopy (OLYMPUS, CKK 41, Tokyo, Japan). On day 5, the 
HUVECs were fixed and stained to examine cell morphologies. Cells rapidly and actively 
migrated from the endothelial channel into the 3D hydrogel scaffolds (condition-side) 
toward the VEGF-supplemented media channel (Fig. 2B); while significantly less migration 
was observed into the opposite scaffold (control-side) toward the control channel without 
VEGF (Fig. 2D). Confocal microscopy revealed the growth of circular lumen-like structures 
from the HUVEC monolayer into the condition-side hydrogel scaffolds in response to 
VEGF (Fig. 2C). No morphological change was evident in the control-side hydrogel 
scaffolds in immunostained and confocal microscopy images, except that several cells had 
migrated. These cells were not connected to the endothelial monolayer by vascular stalks 
presumably due to the absence of a VEGF concentration gradient across the collagen gel 
(Fig. 2E). These qualitative observations were quantified by counting the number of cells 
that migrated from each opening (total openings: #6, Fig. 2A) into collagen gel scaffolds (by 
ImageJ (http://rsbweb.nih.gov/ij/). We found that 79±9.8 cells migrated and proliferated 
toward the condition-side hydrogel scaffolds per; in contrast, 8±2.3 cells migrated toward 
the control-side hydrogel scaffolds (Fig. 2F). Using this migration assay, we could assess the 
response of an endothelial monolayer to various biochemical stimuli simultaneously via 
achieving the stable concentration gradient toward the fourteen 3D hydrogel scaffolds. The 
QMAS therefore allows us to monitor and quantify angiogenesis under the in vivo-like 
situation with uniform experimental conditions (i.e. uniform 3D hydrogel structure 
conditions & hydrostatic conditions between multiple microchannels) simultaneously and 
with little variability due to the operator’s technique.
Quantitative analysis of HUVEC morphology by bortezomib
Bortezomib (Millennium Pharmaceuticals, Inc., Cambridge, MA) was chosen to 
demonstrate the utility of the QMAS for drug screening. Bortezomib, one of the 14 anti-
angiogenic therapeutic drugs have been approved by the US Food and Drug Administration 
(FDA), exerts its anti-angiogenic effect by decreasing the secretion of vascular endothelial 
growth factor (VEGF) from myeloma cells [32, 33]. We wanted to explore the possibility 
that bortezomib could act directly on the endothelium, independent of the myeloma cells. In 
order to model the in vivo situation (Fig. 1A), we first established endothelial cell 
monolayers on the walls of the channels to mimic in vivo blood vessels through the injection 
of endothelial cells (HUVECs) by the multiple-pipette (drug injection channels (#1 ~ #8).. 
Second, VEGF (40 ng/ml)-supplemented media mimicking the growth factors (i.e. VEGF) 
secreted from the tumor were filled in the VEGF injection channels, and finally, we added 
media containing a range of concentrations of bortezomib in each reservoir all with the 
multiple-pipette (drug injection channels (#1 ~ #8), over a logarithmic range (Fig. S6) & a 
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linear range (Fig. S7)). The response of the HUVECs was monitored daily by phase-contrast 
microscopy for 5 days. Subsequent steps are shown in Supplementary Movie 1.
We first assessed whether the morphological changes were shown in bortezomib treated 
HUVECs (logarithmic concentrations: 0, 10−5, 10−4, 10−3, 10−2, 10−1, and 1 μM (Fig. S6)). 
Typical cobblestone-like morphology of HUVECs was observed at the low concentrations 
of bortezomib (0, 10−5, and 10−4 μM) by day 5, whereas the HUVECs showed some 
elongated morphological shapes without spindle-like shapes when conditioned with a dose 
of 10−3 μM (Fig. S8A). Almost all cells died when exposed to bortezomib at higher 
concentrations (10−2, 10−1, and 1 μM). We investigated whether or not bortezomib-induced 
endothelial cell death was preceded by observable morphological changes [34] by 
monitoring cell behaviors daily with the dose of 10−2 μM (Fig. S9). The morphological 
transition to a spindle-like shape was discernable from day 1, and dead cells, which were 
detached from the cell surface, were observed from days 2 to 5. Consequently, we 
determined that bortezomib-induced endothelial cell death was preceded by a series of 
morphological changes that develop over an extended period. We then screened for the 
morphological changes in finer detail, over a reduced range of bortezomib concentrations 
between 10−3 μM (1 nM) and 10−2 μM (10 nM) (Fig. S7). Using a linear variation in 
concentrations we were able to identify that the morphological changes in HUVECs 
occurred in the range of 4 nM to 6 nM bortezomib (Fig. S8B). Within this narrow range, 
HUVECs neither died nor detached from the surface and only showed slight changes in their 
structures. Almost all cells died at the dose of 8 nM and 10nM, became detached from the 
surface and were washed away during media changes.
We next studied the morphological changes of HUVECs quantitatively, but limited either 
the time period of study or the concentration of bortezomib since HUVECs were unable to 
survive at the higher concentrations (10−2, 10−1, and 1 μM) after 3 days. To analyze the 
morphological changes of HUVECs quantitatively, circularity was calculated from the area 
and perimeter of the traced EC (see SI Materials and Methods). The former equals 4π (Area/
Perimeter2); a circularity of 1.0 indicates a perfect circle, and as the circularity approaches 
0.0, the shape becomes an increasingly elongated ellipse. At the low concentration of 
bortezomib (0, 10−5, 10−4, and 10−3 μM), circularities were > 0.6, whereas circularities were 
< 0.4 when treated with the dose of 10−2 μM (Fig.3A). From these results, we observed that 
HUVEC morphology changed significantly in the concentration range between 10−3 μM and 
10−2 μM, so we performed a second set of experiments over a linear concentration range (0, 
1 (10−3 μM), 2, 4, 6, 8, and 10 nM (10−2 μM)). We found circularity of the HUVECs to be a 
sensitive precursor to cell death, which decreased as the concentration and treatment time 
increased (Fig. 3B). These show that we can demonstrate an effect of bortezomib on the 
morphogenesis of HUVEC in a dose and time-dependent manner by using the QMAS.
Fluorescence imaging of HUVECs stained for VE-cadherin allowed us to quantitatively 
assess disruption of VE-cadherin junctions when cells were cultured over 5 days. 
Breakdown of VE-cadherin was evident through the discontinuity of the green fluorescent 
line labeling the VE-cadherin junctions compared with intact VE-cadherin junctions in the 
case of HUVECs cultured in control medium, with no bortezomib (Fig. 3C). We quantified 
cell junction integrity by measuring the number of gaps observed in the VE-cadherin 
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staining (see Materials and Methods). Endothelial gap formation increased as concentration 
of bortezomib increased for 5 days (0, 10−5, 10−4, and 10−3 μM) (Fig. 3D), demonstrating 
significant but sub-lethal effects at these lower concentrations. No data are presented for 
concentrations of 10−2, 10−1, and 1 μM due to cell death and detachment from the surface. 
These results show that the disruption of adherent junctions contributes to the increase in 
vasculature permeability.
Proliferation rate and cell viability in bortezomib treated HUVECs
We next studied whether or not HUVEC proliferation was affected by the treatment of 
bortezomib using Ki67 expression, a marker of proliferation also used for drug discovery 
[35–37]. Studies were conducted, in HUVECs cultured over 2 days under the logarithmic 
(Fig. S6) and linear concentrations (Fig. S7) of bortezomib. We found that Ki67 was 
expressed at higher levels in the absence of bortezomib (0 μM, average=18.2%), and its 
expression ratio gradually decreased with increasing bortezomib concentration at day 1 
(from 18.2% at 0 μM to 7.8% at 1 μM), but declined more by day 2 (from 18.2% at 0 μM to 
3.6% at 1 μM, Fig.4A). Ki67 expression ranged from 18.5% at 0 nM to 6.70% at 10 nM on 
day 1 and 18.34% at 0 nM to 4.24% at 10 nM on day 2 (Fig. 4B). Ki67 was expressed for 
less than 5% in HUVECs when conditioned with 6 nM of bortezomib, which indicates that 
the proliferation rate varies in a time and dose-dependent manner.
We also hypothesized that the potent anti-angiogenic capacity of bortezomib was in part a 
consequence of regression of blood vessels, so we next evaluated the HUVEC’s cell 
viability on the exposure of the bortezomib. Cell viability did not decrease with the addition 
of bortezomib on day 1 (Fig. 4C & D). On day 2, cell viability was still mostly maintained 
for doses < 4 to 6 nM (cell viability > 80%, Fig. 4D), but was significantly decreased at 
concentrations of 10−2 μM (cell viability < 67 %, Fig. 4D). According to these results, we 
have also shown that the cell viability varies with the time and dose-dependent manner, and 
that bortezomib is capable of inducing the death of HUVECs.
Quantitative analysis of anti-angiogenesis in bortezomib-treated endothelial cells
Vascular endothelial growth factor (VEGF)–induced endothelial cell migration is an 
important component of tumor angiogenesis. VEGF regulates key steps in the angiogenic 
process, including endothelial cell migration and tube formation [38]. To find a treatment 
condition that did not result in significant toxicity for HUVECs and inhibit the growth of 
new blood vessels from pre-existing ones, we studied the effects of bortezomib over a 
logarithmic concentration range of bortezomib on the VEGF induced migration of HUVECs 
using the QMAS.
We found that bortezomib treatment significantly suppressed VEGF-induced migration at 
the higher doses of bortezomib (10−2, 10−1, & 1 μM). Confocal microscopy revealed the 
growth of circular lumen-like structures from the HUVEC monolayer into the collagen 
scaffold in response to VEGF at lower bortezomib concentrations (0, 10−5, 10−4, & 10−3 
μM), but no morphogenesis for doses > 10−2 μM was evident in immunostained and 
confocal microscopy images (Fig. S10A). The formation of circular lumen-like structures 
was preceded by a period of VEGF-induced migration, and was also reduced with increasing 
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dose of bortezomib. We also monitored daily the cellular behaviors at the dose of 10−2 μM 
to assess defects in cell migration due to bortezomib. HUVECs migrated toward the 3D 
hydrogel scaffolds in response to VEGF for 2 days, but those migrated cells regressed after 
3 days (Fig. S10B).
The number of migrated cells generally decreased at doses of < 10−3 μM, but the number 
drastically declined when 10−2 μM was applied (Fig. 5A). The percentage of image area 
occupied by the migrated cells fell dramatically at ~ 10−2 μM, in agreement with our results 
on the number of migrated cells (Fig. 5C). For finer discrimination, we screened for the 
cellular behaviors in the linear concentration range of bortezomib (1, 2, 4, 6, 8, & 10 nM). 
The number of migrated cells and % of area occupied by the migrated cells exhibited a 
nearly linear dependence along the linear dose range region (Fig. 5B & D). As expected, 
cells actively migrated at all heights inside the collagen gel scaffolds at the concentration of 
0 nM, 1nM, and 2nM (Fig. 6A) with lumen-like structures, but at concentrations of 4nM and 
6nM, although endothelial cells started out in the gel, they wound up at the bottom with little 
or no lumen-like structures (Fig. 6B). Neither cell migration nor lumen-like structures 
formed at doses of 8nM and 10nM (Fig. 6C). From these results, we determined that 
bortezomib by itself inhibited VEGF-induced angiogenesis, and were able to identify the 
proper dosage of bortezomib (4 nM & 6 nM) that did not prove fatal toxicity to HUVECs 
while being able to inhibit the growth of new blood vessels from a pre-existing monolayer.
Conclusions
In the current study, we have proposed and described the QMAS as a quantitative anti-
angiogenesis screening assay. Its utility was demonstrated using a known anti-angiogenic 
agent, bortezomib. An important attribute of the QMAS is its ability to screen multiple 
concentrations simultaneously, allowing a side-by-side comparison of the dose- and time-
dependent effects of drug in an in vivo-like situation. Minimizing the need for repeated 
experiments on multiple devices will likely reduce experiment-to-experiment variability, 
and lead to assays that are less sensitive to user experience. With this microfluidic-based in 
vitro assay, we explored the possibility that bortezomib, which has been reported to act 
decreasing the VEGF secretion from myeloma cells [32, 33]. Our results suggest an 
additional mechanism, that bortezomib can inhibit angiogenesis by influencing the 
endothelium directly. In addition, we successfully identified a dosage of bortezomib that did 
not result in fatal toxicity for HUVECs while inhibiting the growth of lumen like structures 
from the intact HUVECs monolayer. The proposed QMAS allows experiments in a more 
biologically relevant microenvironment that represents a compromise between mimicking 
all the complexity of the in vivo condition and current in vitro 2D-based screening systems. 
Thus, QMAS provides quantitative information on the intricacies of cellular behaviors using 
a less labor intensive, time-saving method as compared to previously developed in vitro 
angiogenesis assays. Recently, much effort is being directed towards the design of cancer 
treatment by the combination of anti-angiogenesis drugs and conventional anti-cancer drugs. 
The present QMAS lends itself to assays for combination therapies to search for synergistic 
effects, and studies are underway with combination therapies in our group.
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We acknowledge that there could be several outstanding issues, which must be overcome in 
subsequent designs. These include (1) establishing a longer-term culture in the model; (2) 
conducting a detailed study comparing the QMAS and animal experimental results; (3) 
increasing the number of screening locations; and (4) testing various cell types. 
Nevertheless, this assay can provide a representative tissue specific responses; it can be used 
throughout early drug discovery, from target identification and validation to primary 
screening, lead identification and optimization, and safety and toxicology screening.
Materials and Methods
Cell Seeding & perfusion culture
Human umbilical vein endothelial cells (HUVECs) (Lonza, NJ, USA) or RFP-expressing 
HUVECs (Angio-Proteomie; Boston, MA, USA) were seeded and cultured in the cell 
culture channels in direct contact with collagen hydrogel scaffolds, prepared by diluting a 
4.0-mg/ml solution of type I collagen (BD Biosciences, MA, USA) to 2.5 mg/ml and 
polymerizing at an initial pH of 7.4. The cell culture channels were filled with HUVEC 
suspensions prepared in medium at a density of 2 × 106 cells/ml. After forming an 
endothelial cell monolayer, the reservoirs were added and each conditioned medium was 
injected using a multi-tipped pipette. Flow was then generated through the microfluidic 
channels by an external pump (the withdrawal flow rate=1.33 μl/min, Microsyringe pump, 
HARVARD, USA) and continued throughout the experiment in order to maintain a stable 
concentration profile across the 3D hydrogel scaffolds. The device was then placed in a 
37°C incubator for 5 days. Subsequent steps are shown in Supplementary Movie 1.
Preparation of the microfluidic device
Chips were fabricated using an SU-8 fabrication method and replica molding. An SU-8 
(Microchem, Newton, MA, USA) photoresist was used for the development of SU-8 
microstructures. Both the fabricated PDMS device and glass cover slip were autoclaved and 
dried at 80°C overnight. They were then plasma treated (PDC-001, Harrick, CA, USA) in 
air, and bonded together to form a closed microfluidic channel. After recovering 
hydrophobic surface characteristics in the gel filling region, scaffold material was 
introduced into fourteen gel regions to form a gel scaffold using the manifold layer. In these 
experiments, type I collagen (BD Biosciences, MA, USA) was used as the scaffold material 
and was gelled by incubating for 30 minutes at 37°C. Gel stiffness was varied by adjusting 
the solution pH; we used pre-polymerized collagen solutions (2.5mg/ml) of pH 7.4. 
Following gelation, fibronectin (dilution ratio=1:10, Sigma–Aldrich) was introduced into all 
microfluidic channels to improve the cell attachment, and after treatment for 1 day, fresh 
cell culture medium was injected and the device was placed in an incubator (37°C) for cell 
seeding.
Fixation, imaging, and quantification of cell migration
Image J software (http://rsbweb.nih.gov/ij/) was used to measure % of projected areas and 
number (#) of migrated cells. The F-actin distribution and number of cells involved in 
“capillary -like” networks or tube structures were assessed after 5 days culture in the device. 
Cells were fixed with 4% paraformaldehyde (Sigma–Aldrich) for 15 min at room 
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temperature. During fixation, the pressure head and flow were maintained in experimental 
devices to preserve protein expression and activation. After fixation with 4.0% PFA, actin 
filaments and nuclei were then stained with rhodamine-phalloidin (Sigma–Aldrich) and 4′6-
diamidino-2-phenylindole (DAPI; Sigma–Aldrich), respectively. Fluorescent images were 
obtained using a confocal microscope ((OLYMPUS, FLUOVIEW FV 1000, Tokyo, Japan).
Analysis of gaps and disruption of VE-cadherin
Disruption of VE-cadherin was identified from the analysis of discontinuity of green 
fluorescence at VE-cadherin junctions between HUVECs. Gap area within the disrupted 
VE-cadherin junctions was determined from six images. Gap area was quantified as the ratio 
of pixels within all the gaps and total number of pixels in one image. The average 
percentage of endothelial gap was calculated using Image J software.
HUVEC proliferation and cell viability assays
HUVECs were treated with various concentrations of bortezomib in the model for the 
indicated periods of time. Ki-67, a common proliferation marker, was labeled with rabbit 
polyclonal antibody (Abcam) at 1:500 dilutions to analyze HUVEC proliferation ratio. Cell 
viability was tested using the LIVE/DEAD reduced-biohazard viability/cytotoxicity test 
(Molecular Probes, Invitrogen, Cergy Pontoise, France). Staining and analysis were 
performed as recommended by the manufacturer. Cell number was determined using 
ImageJ. All experiments were repeated at least twice at different times.
Statistical analysis
Numerical values were expressed as means ± SDs of more than three independent 
experiments. Statistical significance was determined via one-way analysis of variance 
(ANOVA). Paired Student’s t-tests were conducted to compare means when the ANOVAs 
indicated a significant difference. Statements of significance were based on P-values < 0.01.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. In vivo anti-angiogenesis application and microfluidic assay
(A) Potential anti-angiogenic therapeutic application in cancer treatment in vivo. (B) 
Schematic view of the QMAS for screening anti-angiogenic therapeutic drugs. (C) 
Significant parts of the QMAS are: (1) 3D hydrogel scaffolds in gel cages (fourteen) mimic 
the extracellular matrix (ECM) in vivo, (2) confluent endothelial cell (ECs) monolayers in 
the cell culture channels (eight) mimic pre-existing blood vessels in vivo, (3) VEGF-
supplemented media in conditioned media channels (seven) mimic the presence of growth 
factors secreted by tumor in vivo, and (4) bortezomib-supplemented media with various 
concentrations in the cell culture channels (eight) mimic the introduction of anti-
angiogenesis drugs in vivo via the circulation.
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Figure 2. High throughput angiogenesis assay
(A) Schematic view of a set of experiments to demonstrate the capabilities of the QMAS as 
an angiogenesis assay in response to chemoattractant gradients; VEGF-supplemented media 
(40 ng/ml) introduced into the VEGF injection channels (#1, #3, #5, & #7, (Fig. S5)) and 
control media without VEGF injected into the VEGF injection channels (#2, #4, #6, & #7,
(Fig. S5)) as reference conditions. (B) Migration of ECs from the endothelial channel into 
the 3D hydrogel scaffolds toward the VEGF-supplemented media channel (condition-side). 
(C) Growth of circular lumen-like structures into the condition-side hydrogel scaffolds in 
response to VEGF (yellow arrowheads, cross-section view). (D) Minimal migration of the 
ECs (white arrowheads) into the opposite scaffold toward the control channel without VEGF 
(control-side). (E) Confocal microscopy confirming the absence of circular lumen-like 
structures toward the control channel without VEGF (cross-section view). (F) Qualitative 
analysis showing the number of cells that migrated from each opening into collagen gel 
scaffolds.
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Figure 3. Quantitative analysis of the influence on HUVEC morphology of bortezomib
(A) Circularities of ECs as a function of bortezomib concentration (0, 10−5, 10−4, 10−3, 
10−2, 10−1, and 1 μM). Circularities were > 0.6 for < 10−3 μM), whereas circularities were < 
0.4 @ 10−2 μM. (B) Circularities of ECs as a function of bortezomib concentration (0, 1 
(10−3 μM), 2, 4, 6, 8, and 10 nM (10−2 μM)). Circularity of the ECs, a sensitive measure of 
cell health, decreased as the concentration and treatment time increased. (C) HUVECSs 
were stained with anti-VE-cadherin followed by Alexa 488. Breakdown of VE-cadherin at 
the doses of bortezomib (10−5, 10−4, & 10−3 μM) was evident through the discontinuity of 
the green fluorescent line labeling the VE-cadherin junctions compared with intact VE-
cadherin junctions in the case of HUVECs cultured in control medium (0 μM). (D) 
Qualitative analysis of cell junction integrity by measuring the number of gaps observed in 
the VE-cadherin staining; endothelial gap number increased with increasing concentration of 
bortezomib at 5 days (0, 10−5, 10−4, and 10−3 μM).
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Figure 4. Proliferation rate and cell viability in bortezomib treated HUVECs
(A) Percentages of proliferation rate over a logarithmic range of bortezomib concentrations 
(0, 10−5, 10−4, 10−3, 10−2, 10−1, and 1 μM). Ki67 was expressed at higher levels in the 
absence of bortezomib (0 μM, average=18.2%), and its expression ratio gradually decreased 
with increasing bortezomib concentration at day 1 (from 18.2% at 0 μM to 7.8% at 1 μM), 
but declined more by day 2 (from 18.2% at 0 μM to 3.6% at 1 μM). (B) Percentages of 
proliferation rate over a linear range of bortezomib concentrations (0, 1 (10−3 μM), 2, 4, 6, 8, 
and 10 nM (10−2 μM)). Ki67 expression ranged from 18.5% at 0 nM to 6.70% at 10 nM on 
day 1 and 18.34% at 0 nM to 4.24% at 10 nM on day 2. (C) Cell viability percentages over a 
logarithmic range of bortezomib concentrations. Cell viability did not decrease with the 
addition of bortezomib < 10−2 μM for 1 day, but significantly decreased at 10−2 μM (cell 
viability < 67 %, day 2). (D) Percentages of cell viability on the dose of linear concentration 
of bortezomib. Cell viability was still mostly maintained for doses < 4 to 6 nM (cell viability 
> 80%, day 2).
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Figure 5. Quantitative analysis of anti-angiogenesis in bortezomib-treated endothelial cells
(A) The number of migrated cells as a function of dose with logarithmic variations in 
concentration of bortezomib (0, 10−5, 10−4, 10−3, 10−2, 10−1, and 1 μM). # of migrated cells 
generally decreased at doses < 10−3 μM, but the number drastically declined when 10−2 μM 
was applied. (B) The number of migrated cells as a function of dose with linear variations in 
concentration of bortezomib (0, 1 (10−3 μM), 2, 4, 6, 8, and 10 nM (10−2 μM)). # of 
migrated cells exhibited nearly a linear dependency along the linear dose range region. (C) 
Percentages of cell migrated area as a function of dose of bortezomib (0, 10−5, 10−4, 10−3, 
10−2, 10−1, and 1 μM). % of area occupied by the migrated cells fell dramatically at the dose 
of 10−2 μM, in agreement with our results on the number of migrated cells. (D) Percentages 
of cell migrated area as a function of dose with linear variations in concentration of 
bortezomib. % of area occupied by the migrated cells exhibited nearly a linear dependency 
along the linear dose range region.
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Figure 6. Projected images showing the effect of bortezomib dose;
(A) Cells actively migrated towards upper, middle, and bottom region of collagen gel 
scaffolds and formed lumen-like structures at concentrations of 0 nM, 1nM, and 2nM. (B) 
At concentrations of 4nM and 6nM, although endothelial cells started out throughout the gel, 
they wound up migrating to the bottom and failed to create lumen-like structures. (C) 
Neither cell migration nor lumen-like structures formed at doses of 8nM and 10nM.
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